• Facets (new session)
• Description
• Metadata
• Settings
  • Rule: ActivityStreamsMapasEquivalentb3sb3sifpdbprdf-labelfacetshttp://dbpedia.org/resource/inference/rules/dbpedia#http://dbpedia.org/resource/inference/rules/opencyc#http://dbpedia.org/resource/inference/rules/umbel#http://dbpedia.org/resource/inference/rules/yago#http://dbpedia.org/schema/property_rules#http://www.ontologyportal.org/inference/rules/SUMO#http://www.ontologyportal.org/inference/rules/WordNet#http://www.w3.org/2002/07/owl#ldpoplwebskos-transurn:det:rdf:labelvirtrdf-labelvirtrdf-urlNone
    
  • Inverse Functional Properties: Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects
  • "Same As": Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects (recommended) Apply to subjects, objects and predicates (not recommended on big datasets) Apply to predicates only (special use cases only)

About: Retapamulin     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : yago:WikicatAlcohols, within Data Space : dbpedia.org associated with source document(s)

Type: Thingdul:ChemicalObjectchemical substancePill (pharmacy)yago:WikicatCarboxylateEstersyago:WikicatNitrogenHeterocyclesyago:Abstraction100002137yago:Agent114778436yago:Alcohol107884567yago:Beverage107881800yago:CausalAgent100007347yago:Chemical114806838yago:Compound114818238yago:Drug103247620yago:DrugOfAbuse103248958yago:Ester114850483yago:Fluid114939900yago:Food100021265yago:HeterocyclicCompound115025397yago:Ketone114926294yago:Liquid114940386yago:Material114580897yago:Matter100020827yago:OrganicCompound114727670yago:Part113809207yago:PhysicalEntity100001930yago:Relation100031921yago:WikicatKetonesdrugyago:Substance100019613yago:Substance100020090yago:WikicatAlcohols New Facet based on Instances of this Class

Retapamulin is a topical antibiotic developed by GlaxoSmithKline. It is the first drug in the new class of pleuromutilin antibiotics to be approved for human use. It is marketed as an ointment under the brand names Altabax and Altargo. Retapamulin was approved by the United States Food and Drug Administration in April 2007 for the treatment of bacterial skin infections such as impetigo. In May 2007, retapamulin received approval in the EU from the European Medicines Agency for the same indication.